197 related articles for article (PubMed ID: 23413016)
1. Genetic blockade of insulin-like growth factor-1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat.
Park MY; Kim DR; Eo EY; Lim HJ; Park JS; Cho YJ; Yoon HI; Lee JH; Lee CT
J Gene Med; 2013; 15(3-4):115-22. PubMed ID: 23413016
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway.
Lee YJ; Imsumran A; Park MY; Kwon SY; Yoon HI; Lee JH; Yoo CG; Kim YW; Han SK; Shim YS; Piao W; Yamamoto H; Adachi Y; Carbone DP; Lee CT
Lung Cancer; 2007 Mar; 55(3):279-86. PubMed ID: 17134788
[TBL] [Abstract][Full Text] [Related]
3. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.
Kim DR; Park MY; Lee CS; Shim SH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
Cancer Gene Ther; 2011 Jul; 18(7):467-77. PubMed ID: 21455254
[TBL] [Abstract][Full Text] [Related]
4. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.
Lee CT; Park KH; Yanagisawa K; Adachi Y; Ohm JE; Nadaf S; Dikov MM; Curiel DT; Carbone DP
Cancer Res; 2004 Sep; 64(18):6660-5. PubMed ID: 15374981
[TBL] [Abstract][Full Text] [Related]
6. Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal cancers.
Wang Y; Adachi Y; Imsumran A; Yamamoto H; Piao W; Li H; Ii M; Arimura Y; Park MY; Kim D; Lee CT; Carbone DP; Imai K; Shinomura Y
J Gastroenterol; 2010 Feb; 45(2):159-70. PubMed ID: 19902140
[TBL] [Abstract][Full Text] [Related]
7. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer.
Lee CT; Park KH; Adachi Y; Seol JY; Yoo CG; Kim YW; Han SK; Shim YS; Coffee K; Dikov MM; Carbone DP
Cancer Gene Ther; 2003 Jan; 10(1):57-63. PubMed ID: 12489029
[TBL] [Abstract][Full Text] [Related]
8. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors.
Kim DR; Park MY; Lim HJ; Park JS; Cho YJ; Lee SW; Yoon HI; Lee JH; Kim YS; Lee CT
Int J Mol Med; 2012 Feb; 29(2):218-24. PubMed ID: 22075951
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro.
Cosaceanu D; Carapancea M; Alexandru O; Budiu R; Martinsson HS; Starborg M; Vrabete M; Kanter L; Lewensohn R; Dricu A
Growth Factors; 2007 Feb; 25(1):1-8. PubMed ID: 17454144
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
13. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2004 Aug; 136(2):416-25. PubMed ID: 15300209
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Denlinger CE; Rundall BK; Jones DR
J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
[TBL] [Abstract][Full Text] [Related]
15. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
Adachi Y; Lee CT; Carbone DP
Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
[TBL] [Abstract][Full Text] [Related]
16. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
Min Y; Adachi Y; Yamamoto H; Ito H; Itoh F; Lee CT; Nadaf S; Carbone DP; Imai K
Cancer Res; 2003 Oct; 63(19):6432-41. PubMed ID: 14559833
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines.
Lee CT; Wu S; Gabrilovich D; Chen H; Nadaf-Rahrov S; Ciernik IF; Carbone DP
Cancer Res; 1996 Jul; 56(13):3038-41. PubMed ID: 8674059
[TBL] [Abstract][Full Text] [Related]
19. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
Sarfstein R; Bruchim I; Fishman A; Werner H
PLoS One; 2011; 6(9):e24468. PubMed ID: 21931726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]